Company Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Latest News
Fed Meeting, Inflation, Boeing, Meta, Apple, Exxon, and More to Watch This Week
DexCom (DXCM) Earnings Expected to Grow: Should You Buy?
Earnings Calendar and Analysis for This Week (July 27-31)
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
Are Medical Stocks Lagging DexCom (DXCM) This Year?
| Sector | Healthcare |
| Industry | Medical Devices |
| Website | https://www.dexcom.com |
| Audit Risk | 2 |
| Board Risk | 7 |
| Overall Risk | 5 |
| Market Cap | 27.61B |
| Trailing P/E | 30.7 |
| Forward P/E | 23.25 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | 2.33 |
| Forward EPS | 3.08 |
| Book Value | 7.66 |
| Price-to-Book | 9.34 |
| Enterprise-to-Revenue | 5.52 |
| Enterprise-to-EBITDA | 20.56 |
| Short Ratio | 3.92 |
| Earnings Date | 07/30/2026 |
| Earnings Call Date | 07/30/2026 |
| Earnings Average | 0.61 |
| Earnings Low | 0.57 |
| Earnings High | 0.66 |
| Revenue Average | 1.29B |
| Revenue Low | 1.28B |
| Revenue High | 1.30B |